INTRODUCTION A differential diagnosis with connective tissue disorders might be needed due to a significant increase in the number of human parvovirus B19 (B19V) cases in adults, usually involving reticular rash and multiple joint pain. CASE DESCRIPTION A 40-year-old woman complained of pain in the joints of hands, knees, fingers, and collarbone, morning stiffness, garland-shaped rash on the entire body, fever (up to 38 °C), palpitations, numbness in the arms, dyspnea, pain in the neck, and headache. The patient was diagnosed with systemic lupus erythematosus (SLE), but the symptoms did not improve with typical treatment. Objective examination of the osteoarticular system showed swelling and pain in the joints of hands, knees, fingers, and collarbone, decreased muscle tone, decreased hand strength, disfiguration and deformation of the small joints of the hands, decreased movements, and walking difficulty. Laboratory workup showed clinically significant abnormalities: estimated sedimentation rate, 15 mm/h; C-reactive protein (CRP), 8.6 mg/l (reference range [RR] <5 mg/l); antinuclear antibodies (ANA), immunoglobulin (IgG), 4.1 (index; RR <0.7). An autoimmune panel performed 3 days later was positive for class II double-stranded DNA (ds-DNA), class 1 liver cytosolic antigen type 1, SP100 antibody, gp210 antibody, and Ku antibody. The day after, IgG to ds-DNA was 76 IU/ml (RR <10 IU/ml). Polymerase chain reaction performed a few days later was negative for B19V. Immunoblot IgG was positive for VP1 protein, VLP protein, and VP2 protein; it was negative for NS1 protein. Immunoblot IgM was positive for VP1 protein, uncertain for VLP and NS1 protein, and negative for VP2 protein. The final diagnosis was SLE (acute course, active phase, activity stage II with immunological changes [ANA+, ds-DNA, LC1, SP100, gp210, Ku-positive] and injury of the skin [“butterfly” facial erythema in the past] and joints [arthralgia syndrome, functional joints insufficiency of second to third degree]), chronic tonsilitis, insomnia, tension headache, cervicalgia with myofascial syndrome, and parvovirus infection. The patient’s symptoms resolved within 1 month: ANA, 0.8 (RR ≤1.2); anti-dsDNA, 12.9 IU/ml (RR ≤46 IU/ml); alanine aminotransferase, 11 U/l (RR ≤33 U/l); aspartate aminotransferase, 12.4 U/l (RR ≤32 U/l); CRP, 0.6 mg/l. The patient was observed over the following year for possible symptoms of SLE, but none were found. ANA was negative (enzyme-linked immunosorbent assay), and absent (immunofluorescence test). DISCUSSION Analyzing the patient’s clinical symptoms, exposure history, and positive serologic test results showing B19V presence supported the diagnosis of acute parvovirus infection. However, the possibility of a first presentation of concomitant SLE could not be excluded because of other positive serologic test results (ANA, Ig to ds-DNA) and evidence of hypocomplementemia. The treatment of parvoviral infection is supportive. Rashes and arthralgia may be treated with anti-inflammatory drugs, as presented in our case. CONCLUSIONS B19V infection can produce a transient autoantibody response and mimic the first presentation of a connective tissue disorder, especially SLE, thus underscoring the importance of obtaining an accurate history. To avoid the incorrect diagnosis of lupus, doctors should take these facts into account during the patient’s examination and treatment.
The rapid global aging of the population has heightened the clinical importance of sarcopenia, an interdisciplinary condition characterized by the progressive and widespread decline in skeletal muscle mass, strength, and function. Now formally recognized as a distinct muscle disease, sarcopenia is a key contributor to frailty, physical disability, and increased healthcare use among older adults. While current research encompasses diverse epidemiological and biological perspectives, the integration of multi-system interactions—such as the gut-muscle axis and immune-muscle crosstalk—within clinical assessment remains a vital area of exploration.This review examines the interplay between etiology, molecular pathogenesis, and contemporary diagnostic standards to characterize the syndrome’s complexity. Global prevalence escalates significantly in institutionalized populations or those over age 80. Pathogenesis is rooted in a disruption of protein homeostasis where catabolic pathways, such as the ubiquitin-proteasome system, overwhelm anabolic signaling—a process triggered by mitochondrial dysfunction, chronic low-grade inflammation, and declining sex hormones. Furthermore, the synthesis of diagnostic protocols from international consortia highlights the transition to strength-priority models to better predict the falls, fractures, and cardiovascular events. Despite significant diagnostic progress, more longitudinal research is necessary to refine population-specific cut-off criteria and identify reliable clinical biomarkers. By consolidating current mechanistic evidence and epidemiological trends, this review shows the necessity for the unified diagnostic protocol and calls for continued interdisciplinary research to improve early detection and preserve physical independence in aging societies.